—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Please provide your email address to receive an email when new articles are posted on . NCCN recommends osimertinib plus chemotherapy or lazertinib plus amivantamab-vmjw as first-line options for EGFR ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

The discussion transitions to biomarker testing as an essential component of lung cancer diagnosis, with Dr. Florez emphasizing that diagnosis remains incomplete until molecular characterization is ...

Please provide your email address to receive an email when new articles are posted on . Most patients with nonsquamous NSCLC treated at academically-affiliated community clinics received ...

Telehealth use at the end of life among Medicare decedents with cancers. Reflex Biomarker Testing Pathway 1.7 2.2; 2.3; 1.0; 1.2 PA Fast-Track & Coverage Clarity 3.1 4.0; 1.7; 2.5; 4.2 Value-Based ...

PD-L1 TPS ≥50% enriches for anti–PD-(L)1 monotherapy benefit, but threshold-based use risks misclassification due to dynamic expression and inter-assay/inter ...

Upfront NGS at NSCLC diagnosis is becoming default as adjuvant EGFR/ALK options expand, necessitating systematic pathways to standardize stage- and histology-specific testing. Turnaround delays and ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Early versus delayed initiation of first-line immune checkpoint inhibitors in metastatic non–small cell lung cancer: A real-world analysis of treatment timing and care context. This is an ASCO Meeting ...